The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial.
J. H. Barton
No relevant relationships to disclose
K. C. Shih
No relevant relationships to disclose
E. Raefsky
No relevant relationships to disclose
D. W. Haines
No relevant relationships to disclose
B. Strike
No relevant relationships to disclose
J. D. Hainsworth
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
D. A. Yardley
No relevant relationships to disclose